WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 |

«Konakion MM Paediatric 2 mg/0.2 ml Roche solution for injection or oral administration Phytomenadione (vitamin K1) Please read all of this leaflet ...»

-- [ Page 1 ] --

Patient Information Leaflet UK

Konakion MM Paediatric 2 mg/0.2 ml Roche

solution for injection or oral administration

Phytomenadione (vitamin K1)

Please read all of this leaflet carefully before your baby or child is given this medicine.

 Keep this leaflet. You may need to read it again.

 If you have any further questions, ask the doctor, nurse or midwife.

 This medicine has been prescribed for your child. Do not pass it on to others. It may harm them even if their symptoms are the same.

 If any of the side effects become serious or troublesome, or if you notice any side effects not listed in this leaflet, please tell the doctor, nurse or midwife.

In this leaflet:

1. What Konakion MM Paediatric is and what it is used for

2. Before your baby or child is given Konakion MM Paediatric

3. How Konakion MM Paediatric is given

4. Possible side effects

5. How Konakion MM Paediatric is stored

6. Further information

1. What Konakion MM Paediatric is and what it is used for Konakion MM Paediatric contains a medicine called phytomenadione. This is a man-made vitamin called

vitamin K1. Konakion MM Paediatric is used for the following:

 Babies who do not have enough vitamin K in their bodies. Giving Konakion MM Paediatric prevents and treats bleeding caused by a lack of vitamin K. This is called ‘vitamin K deficiency bleeding’ (VKDB). This is a serious, but rare condition. All newborn babies are given vitamin K1 with their parent’s permission.

 Babies and young children who may have had too much of certain medicines to thin their blood (called anticoagulants). Konakion MM Paediatric is normally used to treat these children after advice from a specialist haematologist (blood doctor).

Konakion MM Paediatric works by helping your body make blood clotting factors. These blood clotting factors help stop bleeding.

2. Before your baby or child is given Konakion MM Paediatric

Your child must not be given Konakion MM Paediatric if they are allergic (hypersensitive) to:

 Phytomenadione or any of the other ingredients of Konakion MM Paediatric (listed in Section 6:

Further information).

If you are not sure if this applies to your child, talk to the doctor, nurse or midwife before they are given Konakion MM Paediatric.

Take special care with Konakion MM Paediatric

Check with your doctor, nurse or midwife before your child has Konakion if:

 They have a problem with the flow of bile in their body (cholestatic disease). Bile is important in helping the body to use some vitamins.

1 uk-pl-konakion-clean-150415-2mg-0.2ml-amps Taking other medicines Please tell your doctor, nurse or midwife if your child is taking or has recently taken any other medicines.

This includes medicines that you buy without a prescription and herbal medicines. This is because Konakion MM Paediatric can affect the way some medicines work. Also some other medicines may affect the way Konakion MM Paediatric works.

In particular, tell your doctor, nurse or midwife if your baby or child is taking medicines to stop their blood clotting (anticoagulants).

Important information about some of the ingredients of Konakion MM Paediatric Konakion MM Paediatric is essentially ‘sodium free’ as it contains less than 1 millimole sodium (2.64 mg in each millilitre).

3. How Konakion MM Paediatric is given Konakion MM Paediatric can be given to your child by injection into a vein or muscle or by mouth (orally).

How it is given will depend upon what the medicine is being used for and whether your baby was born prematurely. The doctor will decide how much Konakion MM Paediatric your child needs.

Prevention of vitamin K deficiency bleeding Healthy babies delivered at or nearly full term

These babies will be given either:

 A single injection (1 mg) either at birth or soon after, or  By mouth (oral) a first dose (2 mg) at birth or soon after. This is followed by a second 2 mg dose after 4 to 7 days and third 2 mg dose at 1 month. In exclusively formula fed infants the third oral dose can be omitted.

Premature babies or full term babies at special risk of bleeding

• These babies will be given Konakion MM Paediatric as an injection at birth or soon after.

• More injections may be given later if your baby is still at risk of bleeding.

Further doses:

 Babies who are given vitamin K by mouth and who are breast-fed (not given formula milk) may need more doses of vitamin K by mouth.

 Bottle-fed babies given the two doses of vitamin K by mouth may not need any more doses of vitamin K.

This is because it is included in formula milk.

The instructions ‘How to give your baby Konakion MM Paediatric by mouth’ are given later in this section (section 3).

Treatment of vitamin K deficiency bleeding (VKDB)  These babies will be given Konakion MM Paediatric as an injection (usually 1 mg).

 More injections may be given later if your baby is still at risk of bleeding. Some babies may also need a blood transfusion.

Treatment of too much blood thinning medicine Treatment of children who have had too much blood thinning medicine is usually decided by a haematologist (blood doctor).





 Konakion MM Paediatric will be given by injection into one of your child’s veins (IV injection).

 The doctor will usually check your child’s blood for the levels of clotting factors. This check will be made 2 to 6 hours after giving Konakion MM Paediatric.

2 uk-pl-konakion-clean-150415-2mg-0.2ml-amps  If your child still does not have enough blood clotting factors, the doctor may give additional doses of Konakion MM Paediatric.

How to give your baby Konakion MM Paediatric by mouth If your baby was given Konakion MM Paediatric by mouth at birth, you will be asked to give your baby another 2 mg dose. You will give them this by mouth 4 to 7 days after birth.

If your baby is having breast milk and no formula milk you may be asked to give your baby 2 mg doses once a month (by mouth).

The pictures in this leaflet show you how to give the doses to your baby by mouth, using the dispenser provided in the pack. If you are not sure, or have any worries about doing this talk to your health visitor, midwife, doctor or pharmacist.

–  –  –

If you forget to give your baby Konakion MM Paediatric  If you forget to give your baby their dose of Konakion MM Paediatric by mouth, talk to your health visitor, midwife or doctor about when to give the next dose.

 Do not give your baby a double dose to make up for a forgotten dose.

If someone else takes your baby’s Konakion MM Paediatric by mistake, they should talk to a doctor.

If you have any further questions on the use of this medicine, ask your doctor, nurse or midwife.

4. Possible side effects Like all medicines, Konakion MM Paediatric can cause side effects, although not everyone gets them.

The following side effects may happen with this medicine:

Allergic reactions

The signs may include:

 Swelling of your baby or child’s throat, face, lips and mouth. This may make it difficult for them to breathe or swallow.

 Sudden swelling of your baby or child’s hands, feet and ankles.

If your baby or child has an allergic reaction, tell a doctor straight away.

A reaction where the injection was given Rarely this may be severe. Signs include redness, swelling, pain and it may cause a scar.

Reporting of side effects If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

United KingdomYellow Card SchemeWebsite: www.mhra.gov.uk/yellowcard

5. How Konakion MM Paediatric is stored  Konakion MM Paediatric ampoules should be stored in their original packaging to protect them from light.

 Konakion MM Paediatric should be stored at a temperature below 25°C.

 Keep out of the reach and sight of children.

 Do not use Konakion MM Paediatric after the expiry date printed on the pack.

 Do not throw away any whole left over ampoules. Instead, return them to your pharmacist so that they can be disposed of carefully. Only keep them if your doctor tells you to.

6. Further information

–  –  –

Other ingredients are glycocholic acid, sodium hydroxide, lecithin, hydrochloric acid and water for injections.

What Konakion MM Paediatric looks like and contents of the pack Konakion MM Paediatric is a slightly opalescent, pale yellow liquid (‘solution for injection or oral administration’).

Konakion MM Paediatric is supplied in amber coloured glass ampoules in packs of 5 with plastic oral dispensers.

Marketing Authorisation Holder and Manufacturer Roche Products Limited 6 Falcon Way Shire Park Welwyn Garden City, AL7 1TW United Kingdom This leaflet was last revised in May 2015 ------------------------------------------------------------------------------------------------------------------------This information is intended for medical or healthcare professionals only:

The tear-off portion above is intended for the patient

–  –  –

Konakion® MM Paediatric 2 mg/0.2 ml solution for injection or oral administration Phytomenadione (vitamin K1) Please refer to the Summary of Product Characteristics for full prescribing information.

Presentation Amber glass ampoules containing 0.2 ml solution. The solution is clear to slightly opalescent and pale yellow in colour. Excipients are glycocholic acid, lecithin, sodium hydroxide, hydrochloric acid and water for injections. Konakion MM Paediatric 2 mg/ 0.2 ml is essentially ‘sodium free’ as it contains less than 1 mmol sodium (2.64 mg per 1 ml). Cartons of 5 ampoules.

PACKS CONTAIN PLASTIC ORAL DISPENSERS. NOT TO BE USED FOR INJECTIONS.

Posology and method of administration Konakion MM Paediatric 2 mg/ 0.2 ml is for either injection (intravenous or intramuscular) or oral administration.

CAUTION: care is required when calculating and measuring the dose in relation to the baby’s weight (10 times dosing errors are common).

–  –  –

Preterm neonates of less than 36 weeks gestation weighing 2.5 kg or greater, and term neonates at special risk (e.g. prematurity, birth asphyxia, obstructive jaundice, inability to swallow, maternal use of anticoagulants or antiepileptics): 1 mg IM or IV at birth or soon after birth. The amount and frequency of further doses should be based on coagulation status.

Preterm neonates of less than 36 weeks gestation weighing less than 2.5 kg: 0.4 mg/kg (equivalent to 0.04 ml/kg) IM or IV at birth or soon after birth. This parenteral dose should not be exceeded. The amount and frequency of further doses should be based on coagulation status.

There is evidence that oral prophylaxis is insufficient in patients with underlying cholestatic liver disease and malabsorption.

CAUTION: care is required when calculating and measuring the dose in relation to the baby’s weight (10 times dosing errors are common).

Dosing information for preterm babies at birth for the prophylaxis of Vitamin K deficiency bleeding

–  –  –

Further oral doses in breast-fed infants have been advised, but safety or efficacy data for these additional doses is limited.

Therapy of early and/or late vitamin K deficiency bleeding (VKDB) Initially 1 mg IV and further doses as required, depending on clinical picture and coagulation status. Konakion therapy may need to be accompanied by a more immediate effective treatment, such as transfusion of blood or blood clotting factors to compensate for severe blood loss and delayed response to vitamin K1.

Antidote therapy to anticoagulant drugs of the coumarin type There have been no dose ranging studies performed to recommend a specific dose of Konakion MM Paediatric used as an antidote to anticoagulant drugs of the coumarin type in infants and children.

Suggested doses are detailed below. Konakion MM Paediatric must be administered by intravenous injection in these patients. It is advisable that a haematologist is consulted about appropriate investigation and treatment in any infant or child in whom Konakion MM Paediatric is being considered.

For patients on warfarin therapy, therapeutic intervention must consider the reason for the patient being on warfarin and whether or not anticoagulant therapy has to be continued (e.g. in a patient with mechanical heart valve or repeated thrombo-embolic complications) as vitamin K administration is likely to interfere with anticoagulation with warfarin for 2 - 3 weeks. For patients continuing to receive warfarin, the suggested dose for the partial reversal of anticoagulation is 30 micrograms/kg administered by IV injection.

Konakion MM Paediatric is only suitable for the administration of doses of 30 micrograms/kg in children weighing over 13 kg.

The suggested dose of vitamin K for patients requiring a complete reversal of a warfarin overdose is 250-300 micrograms/kg administered by IV injection. It should be noted that the earliest effect seen with vitamin K treatment is at 4 to 6 hours and therefore, in patients with severe haemorrhage, replacement with

–  –  –

Method of administration Konakion MM Paediatric can be administered by intramuscular or intravenous injection or by oral administration depending on the indication.

At the time of use, the ampoule contents should be clear. Following incorrect storage, the contents may become turbid or present a phase-separation. In this case the ampoule must not be used.

Parenteral use: For the administration of injection volumes of 0.04 ml (0.4 mg) to 0.1 ml (1 mg), 0.5 ml syringes with 0.01 ml gradations are recommended. Undiluted Konakion MM Paediatric is compatible with

0.5 ml syringes supplied by B.Braun.



Pages:   || 2 |


Similar works:

«AMMA HEALTH & SAFETY ENVIRONMENT ADVISORY GROUP 21 FEBRUARY 2014 MEETING DRUG AND ALCOHOL TESTING UPDATE Background Onsite drug and alcohol testing continues to be the subject of ongoing debate and  discussion, with the latest decision in the Endeavour Energy case (Attachment B) having sparked renewed interest in the issue. In the wake of the latest Endeavour Energy ruling and the earlier case law, AMMA has  been vocal in the media (Attachment A), emphasising it is the companies that run...»

«001-ID-0216_Guide_to_ID_for_Schools A Guide to the Control of Infectious Diseases Schools In This booklet is a guide to infectious diseases which affect children and staff in schools. The guide provides information on incubation period and symptoms, method of spread and minimum control measures for selected diseases and conditions which are of public health importance. The staff at the Infectious Diseases Program of the Allegheny County Health Department is available for consultation at (412)...»

«441 Freedom Parkway NE Atlanta, GA 30307 http://www.jimmycarterlibrary.gov Record Group 220: Cuban-Haitian Task Force: A Guide to Its Records at the Jimmy Carter Library Collection Summary Creator: RG 220: Department of Health and Human Services. Cuban-Haitian Task Force Title: Cuban-Haitian Task Force Dates: 7/15/80-6/1/81 Quantity: 27 linear feet, 7 linear inches, 63 containers Identification: Accession Number: 80-1 National Archives Identifier: 547 Scope and Content: This collection consists...»

«CURRICULUM OF BACHELOR OF HOMEOPATHIC MEDICAL SCIENCES (BHMS) (Revised 2010) ISSION HIG HER CO MM EDUC ATIO N HIGHER EDUCATION COMMISSION ISLAMABAD 1 CURRICULUM DIVISION, HEC Dr. Syed Sohail H. Naqvi Executive Director Prof. Dr. Altaf Ali G. Shaikh Member (Acad) Mr. M. Javed Khan Advisor (Acad) Ms. Ghayyur Fatima Director (Curri) Dr. M. Tahir Ali Shah Deputy Director (Curri) 2 CONTENTS 1. Curriculum for Bachelor of Homeopathic Medical 7 Sciences 2. Objective of the course 8 3. Scheme of Studies...»

«A brief guide to emerging infectious diseases and zoonoses WHO Library Cataloguing-in-Publication data World Health Organization, Regional Office for South-East Asia. A brief guide to emerging infectious diseases and zoonoses.1. Communicable Diseases, Emerging 2. Zoonoses – epidemiology – prevention and control.3. Virus Diseases. 4. Bacterial Infections. 5. Parasitic Diseases. 6. Pest Control ISBN 978-92-9022-458-7 (NLM classification: WA 110) © World Health Organization 2014 All rights...»

«Oxford UnitedHealthcare® Oxford Clinical Policy OBSTRUCTIVE SLEEP APNEA TREATMENT Policy Number: OUTPATIENT 020.32 T2 Effective Date: October 1, 2016 Table of Contents Page Related Policies INSTRUCTIONS FOR USE CONDITIONS OF COVERAGE BENEFIT CONSIDERATIONS COVERAGE RATIONALE DEFINITIONS APPLICABLE CODES  Orthognathic (Jaw) Surgery DESCRIPTION OF SERVICES CLINICAL EVIDENCE U.S. FOOD AND DRUG ADMINISTRATION REFERENCES POLICY HISTORY/REVISION INFORMATION. 25 INSTRUCTIONS FOR USE This Clinical...»

«Cochlear Implantation in the Difficult Ear May 2013 TITLE: Cochlear Implantation in the Difficult Ear SOURCE: Grand Rounds Presentation, Department of Otolaryngology The University of Texas Medical Branch (UTMB Health) DATE: May 23, 2013 RESIDENT PHYSICIAN: Benjamin Walton, MD FACULTY PHYSICIAN: Dayton Young, MD, MD FACULTY PHYSICIAN: Tomoko Makishima, MD, PhD DISCUSSANT:, MD SERIES EDITOR: Francis B. Quinn, Jr., MD ARCHIVIST: Melinda Stoner Quinn, MSICS This material was prepared by resident...»

«Showing the truth, saving lives: the case for S A LU T O PR E P O A P H S O O VI MU ND N I pictorial health warnings WOR L NO TO D DAY BACCO 31 MA Y 200 9 Showing the truth, saving lives: the case for pictorial health warnings Contents Introduction pg. 02 The importance of packaging pg. 05 Consumers do not know enough about the health risks of tobacco use pg. 07 Health warnings on packages do work pg. 08 How to make warnings most effective pg. 10 Countering tobacco industry arguments against...»

«Oral Appliance Treatment for Obstructive Sleep Apnea: An Update Kate Sutherland1,2, Olivier M. Vanderveken3,4, Hiroko Tsuda5, Marie Marklund6, Frederic Gagnadoux7,8,9, Clete A. Kushida10, Peter A. Cistulli1,2 on behalf of the ORANGE-Registry (Oral Appliance Network on Global Effectiveness) 1 Centre for Sleep Health and Research, Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia; 2NHMRC Centre for Integrated Research and Understanding of Sleep...»

«A Horrible Hundred Problem Puppy Mills in the United States In recent years The Humane Society of the United States (HSUS) has assisted in rescuing almost 10,000 dogs from more than 50 different puppy mills across the country. While The HSUS stands ready to assist law enforcement with closing down illegal puppy mills whenever feasible, there remain an estimated 10,000 puppy mills across the United States, and many of them are legal. Although most of the dogs at these mass-breeding facilities...»

«World Nutrition Volume 4, Number 6, June 2013 WN Columns World Nutrition Volume 4, Number 6, June 2013 Journal of the World Public Health Nutrition Association Published monthly at www.wphna.org/worldnutrition/ What do you think? Geoffrey Cannon Sao Paulo. This month I continue to state ‘What I believe’. The series helps to explain this column’s new overall title ‘What do you think?’ The beliefs I am outlining are points of view. There is no such thing as a one and only point of view....»

«Undivided Mind Becoming Whole Rodney Smith Wisdom Collection To access the content within the Wisdom Collection, join Tricycle as a Supporting or Sustaining Member JOIN TRICYCLE Over the last half-century, Buddhist practices in the West have grown in popularity. Mindfulness has become associated with stress reduction, enhanced immunological protection, psychological wellbeing, and profound states of happiness. In many cases, mindfulness has been uncoupled from the Buddha’s teaching altogether...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.